The frequency and variety of infections caused by fungi are increasing. However, changes and intercenter and regional differences are observed in the distribution of fungal species over the years. It is important to update the epidemiological data in order to enable early and appropriate treatment. In this retrospective study, the number of fungi isolated from clinical samples, their distribution at the genus/ species level and the variations over the years in Hacettepe University hospital which is a regional center for patients at risk of fungal infection were investigated. For this purpose, laboratory records from 2008- 2019 were examined and 21813 fungal strains isolated from 19636 clinical samples were detected. When the first (2008-2013) and second (2014-2019) six-year periods were compared, a 2.5 fold increase was observed in the number of specimens yielding fungal growth (first period; n= 5620, second period; n= 14016). Fungi were most frequently isolated from urine (45.0%), lower respiratory tract (30.7%) and blood (6.8%) samples. Mould isolation rate in all samples increased significantly in the second six-year period (from 8.3% to 10.6%, p≤ 0.001). As expected, the most frequent yeast was Candida albicans (57.0%) and mould was Aspergillus fumigatus complex (50.4%). In the second six-year period, isolation of C.albicans (59.3% to 56.0%, p≤ 0.001) among yeasts and A.fumigatus complex (58.1% to 48.0%, p≤ 0.001) among moulds decreased significantly. In urine specimens, most common fungi were C.albicans (49.8%), Candida glabrata complex (15.6%), Candida tropicalis (8.9%) and Candida kefyr (7.5%). In lower respiratory tract specimens, the most common mould was A.fumigatus complex (51.2%), which has decreased from 63.7% in the first six years to 47.1% in the second period (p≤ 0.001). Over the same period, other Aspergillus species (from 25.5% to 34.1%, p= 0.002) and non-Aspergillus moulds (from 36.3% to 52.9%, p≤ 0.001) were increased. In blood samples, C.albicans (44.4%), Candida parapsilosis complex (21.5%) and C.glabrata complex (13.0%) were the most frequent species. In the second six-year period, the frequency of C.albicans decreased from 47.3% to 42.2% (p= 0.059) and the frequency of C.glabrata complex increased from 9.5% to 15.5% (p≤ 0.001) when compared to the first period. For the sterile specimens other than blood, the most common species were C.albicans (37.8%), C.glabrata complex (9.1%) and C.parapsilosis complex (4.7%). However, the number of fungal isolates and the distribution of the species showed great variation over the years. In our center, a substantial increase in the number of fungal strains isolated from the clinical specimens were observed over a 12-years period. In addition and similar to previously published reports, the increase of strains belonging to species with decreased antifungal susceptibility and/or species with unknown susceptibility were detected. The use of local data is required in order to implement early and appropriate antifungal treatment because of inter-center and regional differences observed in epidemiological trends regarding the distributions of fungal genera and species. Surveillance studies to be conducted with the participation of large and sufficient numbers of centers in our country, as we have done for our center, will also contribute to approaches regarding the management of fungal infections by revealing the epidemiological data in a comprehensive manner.
ÖZEnterobacteriaceae üyelerinde görülen genişlemiş spektrumlu beta-laktamaz (GSBL), özellikle klinikte yaygın olarak kullanılan sefalosporin grubu antibiyotiklere direnç gelişmesine neden olan bir enzimdir. GSBL üretiminin erken ve doğru olarak tespit edilmesi, antimikrobiyal tedavi ve enfeksiyon kontrolü için önemlidir; ancak bu amaç için kullanılan yöntemler zaman alıcıdır (24-48 saat). Bu çalışmanın amacı, GSBL üreten bakterilerin kısa sürede tespit edilmesine imkan veren, akım sitometrisi temelli bir test yönteminin belirlenmesidir. Çalışmaya, 2012-2013 yılları arasında izole edilmiş olan, GSBL üreten 38 (29 Escherichia coli, 9 Klebsiella pneumoniae) ve GSBL üretmeyen 10 (5 E.coli, 5 K.pneumoniae) Enterobacteriaceae suşu dahil edilmiştir. İzolatların tanımlanması ve antibiyotik duyarlılık testleri, Phoenix TM 100 otomatize sistemi (Becton Dickinson, ABD) ile yapılmıştır. GSBL pozitif izolatlar polimeraz zincir reaksiyonu yöntemiyle bla TEM , bla SHV , bla CTX-M1 , bla CTX-M2 ve bla CTX-M9 beta-laktamaz genlerinin varlığı açısından araştırılmıştır. Toplam 38 izolatın 36'sında en az bir GSBL geni tespit edilirken, iki E.coli izolatında gen tespit edilmemiştir. Akım sitometrisi yöntemi kullanılarak, sefalosporin [seftazidim (CAZ) veya sefotaksim (CTX)] ve klavulanik asit (CLA) kombinasyonuyla muamele edildiğinde ölen hücre yüzdeleri, sadece sefalosporin (CAZ veya CTX) ile muamele sonrası ölen hücre yüzdelerine oranlanmıştır. CAZ ve CTX için CLA indeks değerleri (CAZ-CLA ve CTX-CLA indeksi) elde edilmiştir. İndeks değerin en az bir sefalosporin için 1.5'ten daha büyük olması GSBL pozitif olarak değerlendirilmiştir. Çalışmamızda, GSBL pozitif olan izolatların genotipik özelliklerine göre CTX-CLA indeksi ortalamaları 1.14 ile 7.22; CAZ-CLA indeks ortalamaları ise 0.85 ile 5.6 arasında bulunmuştur. GSBL pozitif 38 ve GSBL negatif 10 izolattan oluşan iki grup değerlen-dirildiğinde; hem CAZ-CLA hem de CTX-CLA indeksi için iki grup arasında istatistiksel olarak anlamlı fark olduğu saptanmıştır (p< 0.005). CTX-CLA ve CAZ-CLA indeksleri istatistiksel olarak karşılaştırıldığında ise, CTX-CLA indeksinin GSBL pozitifl eri saptayabilme özelliğinin daha iyi olduğu belirlenmiştir (p= 0.001).
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
customersupport@researchsolutions.com
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.